What is it about?
Insulin resistance (IR) is a risk factor for neurodegeneration. In this study we investigated the synergistic ameliorative effect of peroxisome proliferator‐activated receptor agonists on the neuronal pathology associated with IR.
Featured Image
Photo by Bret Kavanaugh on Unsplash
Why is it important?
This study aimed to investigate the synergistic ameliorative activity of the PPAR agonists (fenofibrate and pioglitazone) on hippocampal structure and function in HFD‐ and STZ‐induced rat models of insulin resistance. The PPARα/γ agonists were shown to play a vital ameliorative role in hippocampal neurodegeneration. This has been demonstrated in their regulation of inflammatory processes, reduction of oxidative stress, and control of protein aggregation. This study also reveals that combined PPARα/γ agonists have stronger neuroprotective capacities than either PPARα or PPARγ agonists alone
Perspectives
Writing this article was so exciting as ideas were drawn from my colleagues, with intellectual contributions from my teachers and supervisors. This study should encourage the use of combined therapy in the management of metabolic diseases and neurodegenerative disorders.
Olumayowa Idowu
Osun State University, Osogbo, Nigeria
Read the Original
This page is a summary of: The synergistic ameliorative activity of peroxisome proliferator‐activated receptor‐alpha and gamma agonists, fenofibrate and pioglitazone, on hippocampal neurodegeneration in a rat model of insulin resistance, Ibrain, August 2022, Wiley,
DOI: 10.1002/ibra.12059.
You can read the full text:
Contributors
The following have contributed to this page
